（文章来源：每日经济新闻） 每经AI快讯，2月5日，复星医药(600196.SH)公告称，公司控股子公司复宏汉霖与Eisai签订《许可协 议》，授予Eisai于日本及领域（即用于肿瘤适应症治疗）开发、生产及商业化斯鲁利单抗注射液的权 利。协议包括至多15,501万美元的首付款、监管里程碑款项，以及至多23,333万美元的销售里程碑款项 和特许权使用费。该合作有助于进一步拓展复星医药产品的海外市场。但药品研发具有不确定性，且相 关款项的收取亦存在不确定性。 ...

Core Viewpoint - Maiwei Biotech has received registration approval for two biosimilar drugs, 9MW0311 and 9MW0321, from the Drug Regulatory Authority of Pakistan, marking a significant milestone in the company's global commercialization strategy [1][4]. Drug Information - 9MW0311 (Rexeva) is approved for osteoporosis treatment in postmenopausal women at high risk of fractures, with a specification of 60mg and registration number 127267 [1]. - 9MW0321 (Denosu) is approved for treating giant cell tumor of bone (GCTB) in adults and adolescents, with a specification of 120mg and registration number 127268 [2]. Market Potential - Pakistan, with a population of 240 million, represents a significant emerging market for pharmaceuticals, driven by increasing medical demand [1]. - The global market for denosumab drugs for osteoporosis treatment is projected to reach $1.317 billion in 2024 [2]. International Expansion - The company has signed formal cooperation agreements with 30 countries, including Brazil, Colombia, and Indonesia, to expand the market for 9MW0311 and 9MW0321 [3]. - Registration applications for these drugs have been submitted to five additional countries, including Jordan and Egypt, with more applications in preparation [3]. Competitive Advantage - The approval of these biosimilars enhances the company's core competitiveness and supports its ongoing efforts to penetrate emerging markets [4].